Related Experiment Videos
Modifying the specificity and activity of the Enterobacter cloacae P99 beta-lactamase by mutagenesis within an M13
N O Siemers1, D E Yelton, J Bajorath
1Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA. siemers@bms.com
Abstract:
A library of Enterobacter cloacae P99 beta-lactamase mutants was produced to investigate the importance of residues 286-290 for substrate binding and catalysis and to characterize mutants with altered specificities and activities for various 3'-substituted cephalosporins. This region of the enzyme is a component of the active site that has not been implicated as participating in the catalytic mechanism but, based on molecular modeling, should contact the 3' substituents of cephalosporins. Random mutagenesis was carried out within an M13 phage vector by hybridization mutagenesis, and the phage library could be highly enriched for active beta-lactamase genes by incubation of infected bacteria with beta-lactam antibiotics. The mutants were characterized by Michaelis-Menten kinetic analyses with several cephalosporin substrates and spanned a 25-fold range of k(cat), 24-fold range of K(m), and 6-fold range of k(cat)/K(m) values. All five amino acid positions were found to be permissive to substitution, but the active mutant proteins carried substitutions that likely maintained the structure of the region. Serine 287 was the least permissive to change, requiring small, uncharged residues for retention of catalytic activity. The variation of Michaelis-Menten kinetic parameters observed in these enzymes was shown to be significant in the context of in vitro cytotoxicity assays with the cephalosporin-doxorubicin prodrug C-Dox and is suitable for experiments to probe the relationship between enzyme kinetics and efficacy in enzyme-prodrug approaches to targeted therapy.
Insights
Mutating key residues in Enterobacter cloacae P99 beta-lactamase altered substrate specificity and activity. This research is vital for developing novel enzyme-prodrug therapies for targeted cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Enzyme kinetics
Background:
- Enterobacter cloacae P99 beta-lactamase is crucial for antibiotic resistance.
- Residues 286-290 in the active site are hypothesized to interact with cephalosporin 3' substituents.
- Understanding these interactions can inform the design of targeted therapies.
Purpose of the Study:
- To investigate the role of residues 286-290 in beta-lactamase substrate binding and catalysis.
- To characterize mutants with altered specificities and activities for 3'-substituted cephalosporins.
- To assess the relevance of kinetic variations in enzyme-prodrug cytotoxicity assays.
Main Methods:
- Random mutagenesis using hybridization mutagenesis in an M13 phage vector.
- Enrichment of active beta-lactamase genes by antibiotic selection.
- Michaelis-Menten kinetic analyses with various cephalosporin substrates.
Main Results:
- All five amino acid positions (286-290) were permissive to substitution, with active mutants maintaining structural integrity.
- Serine 287 substitutions required small, uncharged residues for catalytic activity.
- Kinetic parameters (k(cat), K(m), k(cat)/K(m)) varied significantly across mutants.
Conclusions:
- Residues 286-290 play a significant role in the catalytic activity and substrate specificity of Enterobacter cloacae P99 beta-lactamase.
- Mutant kinetic variations are relevant for enzyme-prodrug approaches, particularly in cytotoxicity assays with cephalosporin-doxorubicin prodrugs.
- This study provides a foundation for optimizing enzyme kinetics in targeted cancer therapy.